NEW DELHI: India is bracing for possible disruptions to its pharmaceutical industry – where the American market accounts for almost a third of exports – during Donald Trump’s presidency. Among the firms that manufacture generic medicines and exports its products to the United States is Bangalore-based pharmaceutical company Bioplus Life Sciences.
What makes these developments particularly exciting is what’s driving it. New report predicts pharmaceutical market to soar past $242 billion by 2031 — here’s what’s driving the massive growth first appeared on The Cool Down.
Mohali today raided the premises of a pharmaceutical unit at Baddi after 12,000 sedative tablets of Alprazolam 0.5 mg were seized from a person. He was also in possession of 1 kg heroin following which an FIR was registered against him two days ago by ANTF Ludhiana.
International pharmaceutical group Servier has expanded its partnership with Google Cloud to accelerate the research and development (R&D) of pharmaceuticals. Servier and Google Cloud have entered into an expanded five-year agreement that will see Servier using Google Cloud’s AI offerings for R&D.
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) stands against other biotech stocks with the biggest upside potential.
Exports from Indore’s Special Economic Zone (SEZ) decreased by approximately 6.50 per cent to Rs 9,766.53 crore in the first nine months of 2024-25, primarily due to reduced demand from pharmaceutical units.
The Health and Family Welfare Department in Tripura has issued an order prohibiting the use of any IV fluids manufactured in 2023 by West Bengal Pharmaceutical, effective immediately.
Bajaj Healthcare shares hit a record high of Rs 655 and rallied 17% on the BSE in Friday’s intraday trade after it received an exclusive right to make and market Magtein in India, from Threotech
The Department of Health and Human Services, Office of Inspector General (“OIG”) recently released a favorable advisory opinion, OIG Advisory
Revenue grew to over $400 billion, but still missed growth targets.